Should I Buy VYNE? VYNE 2026 Analysis

Should You Buy Vyne Therapeutics Inc (VYNE) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

0.570

1 Day change

0.35%

52 Week Range

2.940

Analysis Updated At

2026/01/26

Vyne Therapeutics Inc (VYNE) is not a strong buy at the moment for a beginner investor with a long-term strategy. The lack of positive trading signals, neutral insider and hedge fund activity, absence of recent news or significant catalysts, and weak financial performance make it prudent to hold off on buying this stock right now.

Technical Analysis

The MACD histogram is negative and contracting, indicating bearish momentum. RSI is neutral at 71.743, and moving averages are converging, showing no clear trend. Key support is at 0.559, and resistance is at 0.585. The stock is currently trading below the pivot level of 0.572 in pre-market, with a -2.03% change.

Options Data

Positive Catalysts

Revenue increased by 39.67% YoY in Q3 2025, and gross margin remains at 100%.

Neutral/Negative Catalysts

Net income dropped significantly by -40.12% YoY, and EPS declined by -41.38% YoY. No recent news or significant trading trends from insiders or hedge funds. The stock is showing bearish momentum in technical indicators.

Financial Performance

In Q3 2025, revenue increased by 39.67% YoY to $169,000. However, net income dropped to -$7,280,000, down -40.12% YoY, and EPS fell to -0.17, a -41.38% YoY decline. Gross margin remained at 100%.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No analyst rating or price target changes available.

2 Analyst Rating

Wall Street analysts forecast VYNE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for VYNE is 2 USD with a low forecast of 2 USD and a high forecast of 2 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 0.565

Low

Averages

High

Current: 0.565

Low

Averages

High

H.C. Wainwright

Joseph Pantginis

Buy

Neutral

downgrade

AI Analysis

2025-07-30

Reason

H.C. Wainwright

Joseph Pantginis

Price Target

AI Analysis

2025-07-30

downgrade

Buy

Neutral

Reason

H.C. Wainwright analyst Joseph Pantginis downgraded VYNE Therapeutics to Neutral from Buy.

H.C. Wainwright

Buy

Neutral

downgrade

$4.50

2025-07-30

Reason

H.C. Wainwright

Price Target

$4.50

2025-07-30

downgrade

Buy

Neutral

Reason

H.C. Wainwright downgraded VYNE Therapeutics to Neutral from Buy and removed the firm's prior $4.50 price target after the company's Phase 2b trial assessing repibresib in nonsegmental vitiligo did not achieve its primary endpoint and also missed the secondary endpoint. The Phase 2b result is "a surprise to us" that "puts the company in a precarious position," the analyst tells investors. While stating that the company ends this trial in "a relatively stable financial position," the firm says the current risk profile "pushes us to the sidelines," pending visibility on the path forward for repibresib, additional VYN202 data and/or the acquisition of new assets to pursue.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for VYNE

Unlock Now

VYNE Should I Buy

VYNE Should I Buy

Should You Buy Vyne Therapeutics Inc (VYNE) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch